Literature DB >> 20056482

Respiratory viruses, a common microbiological finding in neutropenic children with fever.

Anna Lindblom1, Vivek Bhadri, Stefan Söderhäll, Lars Ohrmalm, Michelle Wong, Oscar Norbeck, Cecilia Lindau, Maria Rotzén-Ostlund, Tobias Allander, Daniel Catchpoole, Luciano Dalla-Pozza, Kristina Broliden, Thomas Tolfvenstam.   

Abstract

BACKGROUND: Febrile neutropenia is a common complication in children undergoing chemotherapy for malignancies. A microbial agent is only identified in 15-30% of the fever episodes and corresponds mostly to bacterial findings.
OBJECTIVE: To investigate viral infections as possible etiologic agents in episodes of febrile neutropenia. STUDY
DESIGN: Nasopharyngeal aspirates (NPAs) from patients presenting with neutropenic fever at two pediatric oncology wards in Sweden and Australia were analyzed with a conventional virus-diagnostic approach and RT-PCR. Coupled blood samples were analyzed for the detection of CMV, EBV, adenovirus and erythrovirus. Bacterial blood culture was performed routinely.
RESULTS: Conventional virus-diagnostic approach coupled to routinely performed bacterial analyzes revealed an infectious agent in 29% compared to 60% when using PCR. By adding PCR, a viral pathogen was detected in 46% of the NPAs and in 4% of the blood samples collected. In half of the patients with bacteremia, respiratory tract viruses were co-detected.
CONCLUSION: Respiratory viruses were frequently detected in NPAs suggesting a significant role of viral infections in children presenting with neutropenic fever. The meaning of these findings needs to be further evaluated but has the potential to individualize infection treatment and to reduce the extensive use of antibiotics in immunocompromised children with neutropenia.

Entities:  

Mesh:

Year:  2010        PMID: 20056482      PMCID: PMC7108298          DOI: 10.1016/j.jcv.2009.11.026

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


Background

Infections are the major cause of morbidity and mortality in children experiencing neutropenia secondary to chemotherapy. Identification of neutropenic episodes and the use of promptly administered empiric broad spectrum antibiotics has reduced mortality to below 5%. As a consequence, this patient group is under high antibiotic pressure and risks both the selection of and colonization by fungi and multi-resistant bacteria. Viral infections, especially respiratory viral pathogens, account for significant morbidity in children in general. It is therefore likely that an over-representation of viral infections is also present during febrile episodes in children with neutropenia. However, diagnostic and therapeutic options are scarce and have not motivated extensively investigation. Causative agents are only detected in 15–30% of the cases, and an etiological search of microbiological agents during febrile neutropenic episodes is required to strengthen the clinical management of this group of patients.2, 3

Objective

The objective with the study was to investigate viruses role as possible etiological agents in children under cancer treatment presenting with neutropenic fever.

Study design

The study was conducted at the pediatric oncology units at the Children's Hospital at Westmead, Sydney, Australia, and Astrid Lindgren Children's Hospital at the Karolinska University Hospital, Stockholm, Sweden, respectively. The study period was 1 year starting in January 2007. All children with a neutropenic febrile episode defined as an axillary temperature >38.0 °C on two occasions 60 min apart or ≥38.5 °C at one occasion and an absolute neutrophil count ≤500 cells/mm3 were invited to participate in the study. After informed consent was obtained, paired nasopharyngeal aspirates (NPAs) and peripheral blood samples were collected. Blood cultures were obtained for routine laboratory assessments and additionally bacteria sampling was performed as guided by symptoms. Only the results from the blood cultures are presented in the study. Clinical data were extracted from the medical journals. Conventional viral detection, immunofluoresence (IF) and viral culture, were performed at both the study sites respectively using the local accredited protocols. NPAs were initially analyzed by monoclonal antibodies and immunofluoresence (IF) detecting parainfluenzavirus (PIV), influenza (Flu) A and B virus, and respiratory syncytial virus (RSV). Viral cultures of NPA samples were monitored for cytopathic effect (CPE), with confirmatory IF performed on cultures with positive CPE. Pathogens detectable included herpes simplex virus (HSV) 1 and 2, varicella zoster virus (VZV), enterovirus (EV), RSV, adenovirus (AdV), PIV1-3, Flu A,B and CMV. Rhinovirus (HRV) was only detectable by viral culture within the Children's Hospital at Westmead's Laboratory. For the detection of viral nucleic acid, NPAs and blood samples were batch analyzed at the Karolinska University Hospital using local accredited methods; total nucleic acid was extracted from NPAs and analyzed using real-time semi-quantitative PCR targeting a panel of respiratory viruses; RSV, Flu A and B, PIV 1-3, EV, AdV, HRV, bocavirus (HBoV), metapneumovirus (hMPV), coronaviruses (CoV) NL63/OC43/229E/HKU1 and KI/WU polyomaviruses (KIPyV/WUPyV).4, 5 Quantitative real-time PCR was also used for the DNA detection of CMV in total nucleotide extracted peripheral blood, AdV in total nucleotide extracted plasma, and EBV and human erythrovirus 1-3 in total nucleotide extracted serum and NPA.6, 7 Bacterial analysis was performed by the Local Clinical Microbiology Laboratory by accredited methods after sampling as per normal clinical routines. The results of the expanded viral analyzes were not available to clinicians in real time. Group comparisons were performed by Kruskal–Wallis test for clinical parameters (Graph Pad Software).

Results

In total, 130 patients were included in the study. Of them, 40 were excluded due to incomplete sampling (n  = 19) and lack of material for PCR analyzes (n  = 21). Hence, samples were processed from 90 episodes (47 and 43 from Stockholm and Sydney, respectively), obtained from 66 individuals. Of these, 53% were females with a median age of 4.9 years (range 0.4–17.8 years). Sixty-nine percent of the episodes were derived from patients undergoing treatment for a hematological malignancy and 31% for solid tumors. A median of eight episodes were included per month (range 1–10), with no apparent seasonality. Conventional assessment by viral culture and IF on NPA samples revealed 10 (11%) episodes with the presence of one or more viral pathogen (six HRV, three CMV, and one PIV3), all identified at the Sydney study site. In addition, bacteremia was identified in 21 (23%) episodes. In total, with a conventional virus-diagnostic approach, infectious agents were identified in 26 (29%) episodes of febrile neutropenia. NPA samples were further evaluated using real-time PCR targeting the viruses detectable by culture (except for CMV) with the addition of agents not normally detected by culture (HBoV, hMPV, CoV, KIPyV, and WUPyVV). In addition to NPA, peripheral blood samples taken at enrollment were assessed for CMV, AdV, EBV and erythrovirus. The findings are shown in Table 1 . One or more viral pathogens were identified in 44 (49%) episodes overall—in 41 (46%) NPA samples and in 4 (4%) peripheral blood samples. In total, infectious agents were identified in 54 (60%) episodes of febrile neutropenia using a diagnostic approach which included PCR-based virus detection. There were no differences in the frequency of detected pathogens between the patients with a hematological malignancy and the ones with a solid tumor.
Table 1

Microbiological findings by PCR.

Infectious agent and localization of detectionSingle virus in NPACo-presence of virus in NPAVirus in bloodBacteria in bloodVirus and bacteria co-presenceAll episodes with at least one agentAll episodes with no agent found
Episodes (90)n = 21 (23%)n = 9 (10%)n = 4 (4%)n = 10 (11%)n = 11 (12%)n = 54 (60%)n = 36 (40%)



AgentsHRV:10HRV, AdVB19:24 G+HRV:5 G+
AdV:3HRV, HBoVCMV:16 Ga3 G
KIPyV:3HRV, OC43EBVb:1
HKU1:2HRV, WUPyVPIV3:2 G+
HBoV:1
NL63:1KIPyV, EVKIPyVc,1 G+
OC43:1KIPyV, HBoVHboV
RSVB, HKU1
RSVB, HKU1
MPV, NL63



Age (years)4.2 (1.9–17.0)4.3 (1.8–12.6)8.8 (4.5–11.6)3.7 (0.4–16.5)3.7 (1.1–15.2)4.3 (0.4–17.0)6.6 (0.9–17.8)
Solid tumor7 of 214 of 94 of 43 of 102 of 1115 of 5413 of 36
URTS14 (67%)7 (78%)4 (100%)7 (70%)7 (64%)37 (69%)26 (72%)
CRP (mg/L)39 (10–376)62 (16–147)64.5 (42–87)124 (8–431)49 (0–445)59 (0–445)48 (5.3–235)
Days with fever2 (1–7)3 (1–5)2 (1–4)3.5 (1–20)3 (1–19)3 (1–20)2 (1–15)
Days with neutropenia6 (2–22)5 (4–12)3.5 (1–9)6 (2–18)7 (3–32)6 (1–32)6 (1–27)
Days at hospital6 (2–20)7d (5–15)3.5 (2–7)9.5e (6–29)12 (7–29)7 (2–29)6 (0–31)
No of antibiotics3 (2–4)3 (1–4)2.5 (2–3)3 (2–6)3 (3–5)3 (1–6)3 (0–6)
No of antiviralsNone0 (0–1)None0 (0–1)None0 (0–1)0 (0–1)

Abbreviations: AdV, adenovirus; B19, erythrovirus B19; HboV, bocavirus; CMV, cytomegalovirus; CRP, C-reactive protein; EBV, Epstein-Barrvirus; EV, enterovirus; G+, Gram positive bacteria; G−, Gram negative bacteria; HKU1, coronavirus HKU1; MPV, humant metapneumovirus; HRV, humant rhinovirus; KIPyV, KI polyomavirus; NL63, coronavirus NL63; NPA, nasopharyngeal aspirate; OC43, coronavirus OC43; PIV3, parainfluenzaevirus 3; RSV, respiratory syncytial virus; URTS, upper respiratory tract symptoms; WUPyV, WU polyomavirus. Number of antibiotics and antivirals indicate the number of anti-infective drugs administered during in-patient care.

One case with fatal outcome.

Rhinovirus detected in NPA.

Also presented in the “Co-presence of virus in NPA” group.

Significantly larger number of days in hospital as compared to the group with virus in blood (P < 0.05) and episodes with no agent found (<0.05).

Significantly larger number of days in hospital as compared to the group with virus in blood (P < 0.05) and episodes with no agent found (<0.05). Correlations between other clinical parameters were non-significant.

Microbiological findings by PCR. Abbreviations: AdV, adenovirus; B19, erythrovirus B19; HboV, bocavirus; CMV, cytomegalovirus; CRP, C-reactive protein; EBV, Epstein-Barrvirus; EV, enterovirus; G+, Gram positive bacteria; G−, Gram negative bacteria; HKU1, coronavirus HKU1; MPV, humant metapneumovirus; HRV, humant rhinovirus; KIPyV, KI polyomavirus; NL63, coronavirus NL63; NPA, nasopharyngeal aspirate; OC43, coronavirus OC43; PIV3, parainfluenzaevirus 3; RSV, respiratory syncytial virus; URTS, upper respiratory tract symptoms; WUPyV, WU polyomavirus. Number of antibiotics and antivirals indicate the number of anti-infective drugs administered during in-patient care. One case with fatal outcome. Rhinovirus detected in NPA. Also presented in the “Co-presence of virus in NPA” group. Significantly larger number of days in hospital as compared to the group with virus in blood (P < 0.05) and episodes with no agent found (<0.05). Significantly larger number of days in hospital as compared to the group with virus in blood (P < 0.05) and episodes with no agent found (<0.05). Correlations between other clinical parameters were non-significant. Twenty-two episodes had at least one virus detected to which capacity of detection overlapped between the conventional methods and real-time PCR, Table 2 . The conventional techniques could detect a virus in seven (29%) of the 22 episodes with a median threshold cycle (Ct) of 24.4 (range 16.9–32.7). In the samples with a virus detected by only PCR, the median Ct was 33.4 (range 25–38.7).
Table 2

Comparison of molecular and conventional methods in the 22 episodes with virus detected to which capacity of detection overlapped.

Virus detectedPCR (ct)CultureIF
Adenovirus(36.95)Not detectedN/Aa
Adenovirus(36.98)Not detectedN/Aa
Adenovirus(38.66)Not detectedN/Aa
EV, KIPyV(29.88), (33.7)Not detected/N/AaN/Aa
HRV(33.06)Not detectedN/Aa
HRV(35.41)Not detectedN/Aa
HRV(30.16)HRVN/Aa
HRV(28.43)Not detectedN/Aa
HRV(20.26)HRVN/Aa
HRV(34.68)Not detectedN/Aa
HRV(38.03)HRVN/Aa
HRV(26.53)Not detectedN/Aa
HRV(24.95)Not detectedN/Aa
HRV(16.89)HRVN/Aa
HRV(25.59)Not detectedN/Aa
HRV(24.35)HRVN/Aa
HRV(26.06)Not detectedN/Aa
HRV, Adenovirus(33.9), (35.6)Not detectedN/Aa
HRV, Aoca(32.71), (35.10)HRV, N/AaN/Aa
HRV, CMV, WUPyV(36.91), N/A, (26.7)Not detected, CMV, N/AaN/Aa
PIV3(22.9)Not donebPIV3
PIV3(28.19)Not detectedNot detected

Detection not applicable with method.

No culture done.

Comparison of molecular and conventional methods in the 22 episodes with virus detected to which capacity of detection overlapped. Detection not applicable with method. No culture done. Eight individuals had NPA sampled repeatedly during separate neutropenic fever episodes and were assessable to whether the virus had cleared or persisted by real-time PCR. Of these individuals, five demonstrated clearance (after a median of 5.5 weeks, range 2.7–14 weeks), while three had the same virus persistently detectable, two rhinovirus and one HKU1 (after a median of 3.6 weeks, range 3.4–5 weeks). Differences in the clinical picture in patients with different detected pathogens and the group with no detected pathogens were sought for (Table 1). The only statistical significance recorded was longer hospitalization in the groups with bacteremia and co-presence of virus in NPA and in the group with only bacteremia as compared to the groups with disseminated viral infection and with no microbial agent detected. One case with fatal outcome was recorded in the group with bacteria detected in blood.

Discussion

In this report we show that PCR-based viral diagnostics can greatly increase the detection of infectious agents in febrile episodes of neutropenia in children. The addition of assays detecting recently described viruses and viruses difficult to detect by conventional methods also contributed to higher detection rates. It was also noted that the use of a more extended viral culture routine including detection of HRV by one of our study laboratories clearly contributed to a higher yield of positive findings. There are only a few previously reported studies with the aim of detecting a broad range of viruses in children with neutropenic fever in a pediatric oncology setting using PCR-techniques. Christensen et al. reported a prospective study of a population of children on cancer treatment. They detected virus in 10% of oral washes and nasal swabs and noted severe infectious complications in these patients. Conversely, Koskenvuo et al. found evidence of viral infection in 44% of nasal swabs in children with leukemia with no significant association to neutropenia. In the present study we focused only on patients presenting with neutropenic fever and could confirm Koskenvuos high detection rate of respiratory tract viruses but also HRV as the most common detected pathogen. Differences in sampling procedures probably explain the discrepancy between the present study and the study by Christensen et al. Co-presence of a respiratory virus was detected in half of the episodes with bacteremia which also corresponds to what was found in a group of children with acute leukemia. Interestingly, no differences in the clinical picture and parameters were detected in our material except for longer hospitalization in the group of patients with bacteremia and co-presence of respiratory virus and bacteremia alone as compared to the groups with disseminated viral infection and with no microbial agent detected (Table 1). Whether this reflects a more severe clinical picture in group with co-detection of bacteremia and respiratory virus and bacteremia alone or a milder course in the group of patients with disseminated viral infection and no agent detected could not be ruled out in the study. Utilizing PCR-techniques for viral detection has thus the advantage of increased sensitivity as compared to viral culture and antigen detection. It is however not clear whether the detected viral nucleic acid actually represents the direct causative agent of the neutropenic fever. A positive PCR result could also represent a sub-clinical infection, a post-infection viral shedding, or just intracellular non-replicating viral nucleic acid remnants. However, a recent prospective study on repeated sampling of infants showed that the same virus was detected in only 5% of consecutively sampled NPA after 2 weeks, and in these cases only rarely the same virus genotype. Prolonged viral shedding of RSV and influenza A has been reported in children with cancer.12, 13 Of 27 patients studied by Koskenvuo et al. whose follow-up samples were taken 1–11 days after the first one, 23 were negative whereas four patients remained virus-positive. In our present study, eight individuals had NPA sampled repeatedly during separate neutropenic fever episodes of which five demonstrated clearance. Whether the three patients remaining virus positive was due to a persistent infection or a new infection of a different genotype could not be ruled out since we did not perform sequencing. These patients were also sampled with a shorter interval and may have received stronger immunosuppression or represent a more severe underlying disease. However, as indicated by Koskenvuo et al. and our present study, the majority of viruses detected were eventually cleared, supporting the fact that the virus corresponds to an acute infection. In order to decrease the usage of broad spectrum antibiotics, the role of the detected viruses as causative agents needs to be further clarified in future studies by follow-up sampling but also inclusion of controls. It would also be helpful to study the meaning of different viral loads and their correlation to clinical disease. Although disseminated CMV, EBV and AdV have been described as a major cause of morbidity and mortality in children undergoing hematopoietic stem-cell transplantation (HSCT), they have not been thoroughly assessed in children with neutropenia. In this study, these viruses were present in 4% of the febrile episodes and are thus not a significant cause of morbidity in this setting. This is most likely due to a less profound immunosuppression in the majority of these children as compared to patients undergoing HSCT. In the case of erythrovirus infection, it may also reflect the need to analyze bone marrow-samples to find persistent infection where peripheral viremia is low or absent. Several studies have tried to identify risk factors to single out the patients at highest risk of life threatening infections and in need of hospital care with broad spectrum antibiotics, and patients with lower risk and thereby suitable for less broad and even ambulatory treatment.15, 16, 17, 18 By adding PCR-based viral diagnostics to the microbial investigation of children with neutropenic fever, we could greatly enhance the diagnostic sensitivity, but further studies are needed to address causality and viral load association to clinical disease in this group of patients. In the future, application of agile and broad microbial diagnostics may however provide decreased use of antibiotics and individualized infection-management in this group of patients.

Conflicts of interest

All authors declare that they have no conflicting interests.
  18 in total

1.  Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial.

Authors:  A S Petrilli; L S Dantas; M C Campos; C Tanaka; V C Ginani; A Seber
Journal:  Med Pediatr Oncol       Date:  2000-02

2.  Slow clearance of human parvovirus B19 viremia following acute infection.

Authors:  Anna Lindblom; Adiba Isa; Oscar Norbeck; Susanne Wolf; Bo Johansson; Kristina Broliden; Thomas Tolfvenstam
Journal:  Clin Infect Dis       Date:  2005-09-02       Impact factor: 9.079

Review 3.  Febrile neutropenia in children.

Authors:  F Crokaert
Journal:  Int J Antimicrob Agents       Date:  2000-10       Impact factor: 5.283

4.  Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.

Authors:  A Hamidah; A M Rizal; A J Nordiah; R Jamal
Journal:  Singapore Med J       Date:  2008-01       Impact factor: 1.858

5.  Serial viral infections in infants with recurrent respiratory illnesses.

Authors:  T Jartti; W-M Lee; T Pappas; M Evans; R F Lemanske; J E Gern
Journal:  Eur Respir J       Date:  2008-04-30       Impact factor: 16.671

6.  A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation.

Authors:  Elio Castagnola; Vincenzo Fontana; Ilaria Caviglia; Silvia Caruso; Maura Faraci; Francesca Fioredda; Maria Luisa Garrè; Cristina Moroni; Massimo Conte; Giuseppe Losurdo; Franca Scuderi; Roberto Bandettini; Paolo Tomà; Claudio Viscoli; Riccardo Haupt
Journal:  Clin Infect Dis       Date:  2007-10-05       Impact factor: 9.079

7.  Virus infections in children with acute lymphoblastic leukaemia.

Authors:  A W Craft; M M Reid; P S Gardner; E Jackson; J Kernahan; J McQuillin; T C Noble; W Walker
Journal:  Arch Dis Child       Date:  1979-10       Impact factor: 3.791

8.  Respiratory viral infections in children with leukemia.

Authors:  Minna Koskenvuo; Merja Möttönen; Jaana Rahiala; Ulla M Saarinen-Pihkala; Pekka Riikonen; Matti Waris; Thedi Ziegler; Matti Uhari; Toivo T Salmi; Olli Ruuskanen
Journal:  Pediatr Infect Dis J       Date:  2008-11       Impact factor: 2.129

9.  Parvovirus B19 infection in children with acute lymphoblastic leukemia is associated with cytopenia resulting in prolonged interruptions of chemotherapy.

Authors:  Anna Lindblom; Mats Heyman; Igge Gustafsson; Oscar Norbeck; Tove Kaldensjö; Asa Vernby; Jan-Inge Henter; Thomas Tolfvenstam; Kristina Broliden
Journal:  Clin Infect Dis       Date:  2008-02-15       Impact factor: 9.079

10.  Quantification of adenovirus DNA in unrelated donor hematopoietic stem cell transplant recipients.

Authors:  I Gustafson; A Lindblom; Z Yun; H Omar; L Engstrom; I Lewensohn-Fuchs; P Ljungman; K Broliden
Journal:  J Clin Virol       Date:  2008-06-11       Impact factor: 3.168

View more
  20 in total

1.  Febrile illness in high-risk children: a prospective, international observational study.

Authors:  Fabian J S van der Velden; Gabriella de Vries; Alexander Martin; Emma Lim; Ulrich von Both; Laura Kolberg; Enitan D Carrol; Aakash Khanijau; Jethro A Herberg; Tisham De; Rachel Galassini; Taco W Kuijpers; Federico Martinón-Torres; Irene Rivero-Calle; Clementien L Vermont; Nienke N Hagedoorn; Marko Pokorn; Andrew J Pollard; Luregn J Schlapbach; Maria Tsolia; Irini Elefhteriou; Shunmay Yeung; Dace Zavadska; Colin Fink; Marie Voice; Werner Zenz; Benno Kohlmaier; Philipp K A Agyeman; Effua Usuf; Fatou Secka; Ronald de Groot; Michael Levin; Michiel van der Flier; Marieke Emonts
Journal:  Eur J Pediatr       Date:  2022-10-15       Impact factor: 3.860

2.  Flocked nasal swab versus nasopharyngeal aspirate for detection of respiratory tract viruses in immunocompromised adults: a matched comparative study.

Authors:  Lars Ohrmalm; Michelle Wong; Maria Rotzén-Östlund; Oscar Norbeck; Kristina Broliden; Thomas Tolfvenstam
Journal:  BMC Infect Dis       Date:  2010-11-26       Impact factor: 3.090

3.  Febrile neutropenia: significance of elaborated screening for respiratory viruses, and the comparison of different sampling methods, in neutropenic patients with hematological malignancies.

Authors:  Rogier R Jansen; Bart J Biemond; Janke Schinkel; Sylvie M Koekkoek; Richard Molenkamp; Menno D de Jong; Caroline E Visser
Journal:  Virol J       Date:  2013-06-27       Impact factor: 4.099

4.  A prospective multicenter study of microbiologically defined infections in pediatric cancer patients with fever and neutropenia: Swiss Pediatric Oncology Group 2003 fever and neutropenia study.

Authors:  Philipp Agyeman; Udo Kontny; David Nadal; Kurt Leibundgut; Felix Niggli; Arne Simon; Andreas Kronenberg; Reno Frei; Hugo Escobar; Thomas Kühne; Maja Beck-Popovic; Nicole Bodmer; Roland A Ammann
Journal:  Pediatr Infect Dis J       Date:  2014-09       Impact factor: 2.129

5.  Frequent Respiratory Viral Infections in Children with Febrile Neutropenia - A Prospective Follow-Up Study.

Authors:  Martina Söderman; Samuel Rhedin; Thomas Tolfvenstam; Maria Rotzén-Östlund; Jan Albert; Kristina Broliden; Anna Lindblom
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

6.  Immune-Complexed Adenovirus Induce AIM2-Mediated Pyroptosis in Human Dendritic Cells.

Authors:  Karsten Eichholz; Thierry Bru; Thi Thu Phuong Tran; Paulo Fernandes; Hugh Welles; Franck J D Mennechet; Nicolas Manel; Paula Alves; Matthieu Perreau; Eric J Kremer
Journal:  PLoS Pathog       Date:  2016-09-16       Impact factor: 6.823

7.  Respiratory Viruses in Febrile Neutropenic Patients with Respiratory Symptoms.

Authors:  Mohsen Meidani; Seyed Alireza Mirmohammad Sadeghi
Journal:  Adv Biomed Res       Date:  2018-01-22

8.  Assessment of respiratory tract viruses in febrile neutropenic etiology in children and comparison with healthy children with upper/lower respiratory tract infection.

Authors:  Ayse Bozkurt Turhan; Tercan Us; Ener Cagri Dinleyici; Gonca Kilic Yildirim; Nilgun Kasifoglu; Zeynep Canan Ozdemir; Ozcan Bor
Journal:  North Clin Istanb       Date:  2021-01-05

9.  Viral findings in adult hematological patients with neutropenia.

Authors:  Lars Ohrmalm; Michelle Wong; Carl Aust; Per Ljungman; Oscar Norbeck; Kristina Broliden; Thomas Tolfvenstam
Journal:  PLoS One       Date:  2012-05-03       Impact factor: 3.240

10.  Clinical diagnosis of pandemic A(H1N1) 2009 influenza in children with negative rapid influenza diagnostic test by lymphopenia and lower C-reactive protein levels.

Authors:  Lin Wang; Ling-Sai Chang; Ing-Kit Lee; Kuo-Shu Tang; Chung-Chen Li; Hock-Liew Eng; Huey-Ling You; Kuender D Yang
Journal:  Influenza Other Respir Viruses       Date:  2013-11-07       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.